Houston space health nonprofit launches first experiments onboard Blue Origin mission

all aboard

Houston-based health tech organization had experiments on Blue Origin's last mission. Photo courtesy of Blue Origin

Houston's Translational Research Institute for Space Health, or TRISH, conducted cutting-edge research onboard Blue Origin's New Shepard rocket that launched Friday, November 22.

The NS-28 mission sent private astronauts on an 11-minute suborbital journey past the recognized boundary of space known as the Kármán line, according to Blue Origin's website. While on board, astronauts wore a medical-grade BioButton device, known as a BioIntelliSense, that monitored vital signs and biometric readings.

The findings will add to TRISH's Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program and were the first data sets captured from a suborbital flight.

“This initiative enables TRISH to further our research in space medicine by collecting valuable human health data,” Jimmy Wu, TRISH deputy director and chief engineer and assistant professor at Baylor, said in a statement. “New data from suborbital flights builds our understanding of how the human body responds to spaceflight. This holistic view is key in keeping humans healthy and safe in space.”

The experiments were also TRISH's first on a Blue Origin mission.

TRISH, which is part of BCM’s Center for Space Medicine with partners Caltech and MIT, has launched experiments on numerous space missions to date, with each contributing to its EXPAND platform, which compiles research on human health while in space.

In January, TRISH launched six experiments onboard Houston-based Axiom Space's third private astronaut mission to the International Space Station, known as Ax-3. Prior to that, it also sent experiments on board the Ax-2 in May 2023. The research considered topics ranging from changes in astronauts memory before and after space travel to sleep and motor skills.

TRISH also launched experiments onboard SpaceX's Polaris Dawn mission this fall and on the Inspiration4 all-civilian mission to orbit in 2021.

TRISH published its findings from the Inspiration4 mission in the journal Nature this summer. The study showed that "short-duration missions do not pose a significant health risk" to humans onboard. Read more about the team's findings here.

From Your Site Articles
The projects focus on an array of topics from the challenges of harmful space radiation to the reliability of space robots. Photo via Pexels

Rice University awards $150,000 to space researchers

future of space

The Rice Space Institute has awarded $150,000 in seed funding to six university researchers to further their work in space-related science and engineering.

The projects each will receive $25,000 until June 2025, according to Rice. They focus on an array of topics from the challenges of harmful space radiation to the reliability of space robots.

“These projects collectively represent RSI’s commitment to pioneering studies that advance Rice’s space research portfolio,” RSI Director David Alexander, said in a statement.

The projects include:

  • Co-advancement of formal methods and prognostic digital twins for reliability and resilience of space robotics: The project aims to make space robots more reliable by improving the lifespan of robotic components operating in space.
  • Development of 3D-printed waveguide arrays for snapshot spectrometers for Earth remote sensing observations: The project will develop 3D waveguide components and a hyperspectral imaging system that will help provide data on Earth's water cycle. It's led by Tomasz Tkaczyk.
  • Haptic sensory feedback augmentation to mitigate vestibular deficits following microgravity exposure: The project focuses on a device that uses vibrotactile feedback to improve astronauts' balance and movement impairments due to microgravity. It's led by Marcia O’Malley, Vanessa Sanchez, Shane King and Kyra Stovicek.
  • Modeling framework for bioelectricity and its effect on the mechano-biology of wounds to accelerate healing in microgravity environments: The project focuses on the effect of bioelectricity on wound healing in microgravity. It's led by Raudel Avila, Swathi Balaji and K. Jane Grande-Allen.
  • The role of the environment in planet formation: The project will develop a conference at at the Rice Global Paris Center for foster collaboration between Rice, RSI and international institutions for students, researchers and faculty. It's led by Megan Reiter.
  • Spark plasma sintered high-density and lightweight boron nitrides ceramics for radiation shielding applications: The project aims to create boron-nitride ceramics to shield against harmful space radiation. It's led by Robert Vajtai and Abhijit Biswas.

Earlier this year, Alexander was named to the first-ever Texas Aerospace Research and Space Economy Consortium Executive Committee, part of the new Texas Space Commission. TARSEC is composed of representatives of each higher education institution in the state and aims to ensure that Texas remains a "powerhouse" in the space industry, Lieutenant Governor Dan Patrick said in a release.

Meanwhile, The Translational Research Institute for Space Health, or TRISH, which is part of BCM’s Center for Space Medicine, announced plans to launch six more experiments into space this year, focused on topics ranging from motion sickness to genome alterations during space travel.
Earlier this month, TRISH announced the initial selection for its Space Health Ingress Program (SHIP) solicitation. Photo via BCM.edu

Houston organization selects research on future foods in space health to receive $1M in funding

research and development

What would we eat if we were forced to decamp to another planet? The most immediate challenges faced by the food industry and astronauts exploring outside Earth are being addressed by The Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine’s Center for Space Medicine’s newest project.

Earlier this month, TRISH announced the initial selection for its Space Health Ingress Program (SHIP) solicitation. Working with California Institute of Technology and Massachusetts Institute of Technology, the Baylor-based program chose “Future Foods for Space: Mobilizing the Future Foods Community to Accelerate Advances in Space Health,” led by Dr. Denneal Jamison-McClung at the University of California, Davis.

“TRISH is bringing in new ideas and investigators to propel space health research,” says Catherine Domingo, TRISH operations lead and research administration associate at Baylor College of Medicine, in the release. “We have long believed that new researchers with fresh perspectives drive innovation and advance human space exploration and SHIP builds on TRISH’s existing efforts to recruit and support new investigators in the space health research field, potentially yielding and high-impact ideas to protect space explorers.”

The goal of the project is to develop sustainable food products and ingredients that could fuel future space travelers on long-term voyages, or even habitation beyond our home planet.

Jamison-McClung and her team’s goal is to enact food-related space health research and inspire the community thereof by mobilizing academic and food-industry researchers who have not previously engaged with the realm of space exploration. Besides growing and developing food products, the project will also address production, storage, and delivery of the nutrition created by the team.

To that end, Jamison-McClung and her recruits will receive $1 million over the course of two years. The goal of the SHIP solicitation is to work with first-time NASA investigators, bringing new minds to the forefront of the space health research world.

“As we look to enable safer space exploration and habitation for humans, it is clear that food and nutrition are foundational,” says Dr. Asha S. Collins, chair of the SHIP advisory board, in a press release. “We’re excited to see how accelerating innovation in food science for space health could also result in food-related innovations for people on Earth in remote areas and food deserts.”

The human body undergoes specific challenges in space. A new film from TRISH explains the unique phenomenon and how research is helping to improve human life in space. Photo courtesy of NASA

Houston-based organization premieres space health tech documentary

watch now

A Houston space health organization has launched a film that is available to anyone interested in how space affects the human body.

The Translational Research Institute for Space Health, or TRISH, which is housed out of Baylor College of Medicine in consortium with Caltech and the Massachusetts Institute of Technology, announced a new documentary — “Space Health: Surviving in the Final Frontier.” The film, which covers how space affects humans both physically and mentally. It's free to watch online.

“This documentary provides an unprecedented look into the challenges – physical and mental – facing space explorers and the types of innovative research that TRISH supports to address these challenges,” says Dr. Dorit Donoviel, TRISH executive director and associate professor in Baylor’s Center for Space Medicine, in a news release. “We hope the film inspires students and researchers alike to see how their work could one day soon improve the lives of human explorers.”

The documentary interviews a wide range of experts — scientists, flight surgeons, astronauts, etc. — about all topics related to health, like food, medicine, radiation, isolation, and more. Some names you'll see on the screen include:

  • Former NASA astronaut Nicole Stott
  • Active NASA astronaut Victor Glover
  • NASA Associate Administrator Kathy Lueders
  • Inspiration4 Commander Jared Issacman
  • TRISH-funded researchers Level Ex CEO Sam Glassenberg and Holobiome CEO Philip Strandwitz

“Understanding and solving the challenges that face humans in space is critical work,” says Dr. Jennifer Fogarty, TRISH chief scientific officer, in the release. “Not only does space health research aim to unlock new realms of possibility for human space exploration, but it also furthers our ability to innovate on earth, providing insights for healthcare at home.”

TRISH is funded by NASA’s Human Research Program and seeks both early stage and translation-ready research and technology to protect and improve the health and performance of space explorers. This film was enabled by a collaboration with NASA and HRP.

James Hury joins the Houston Innovators Podcast to discuss the role of the Translational Research Institute for Space Health. Photo courtesy of TRISH

Houston innovator talks space health and the future of the commercial sector

houston innovators podcast episode 102

Only about 500 humans have made it to space, which, from a research perspective, isn't a large data set. Yet as commercial space exploration continues and more people make it up into space, new opportunities for space health research are being made available.

"If you look at all the people who have gone into space, they've mostly been employees of nations — astronauts from different governments," says James Hury of the Translational Research Institute for Space Health on this week's episode of the Houston Innovators Podcast. "We're going to start to get people from all different ages and backgrounds."

Hury is the deputy director and chief innovation officer for Houston-based TRISH, and he's focused on identifying space tech and research ahead of the market that has the potential to impact human health in space. From devices that allow astronauts to perform remote health care on themselves to addressing behavioral health challenges, TRISH is supporting the future of space health.

The organization, which is housed out of Baylor College of Medicine and supported by NASA, has a major role to play in the future of space. The Federal Aviation Administration released new space travel regulations that require travelers to contribute something to society. One way to check that box is to collaborate with TRISH on its research.

"If you are willing to go and help participate in experimentation and research endeavors, then you are helping to gain knowledge for all of humankind," Hury says of future space travelers willing to pay tens of millions of dollars to go to space.

TRISH has stood up the first commercial spaceflight medical research program to work with commercial spaceflight crews to bring back crucial research to one database. Called EXPAND — Enhancing eXploration Platforms and Analog Definition — the new collaborative program is meant to address the challenges that humans face on space missions — early detection and treatment of medical conditions, protection from radiation, mental health, team dynamics, and more.

The human aspect of space exploration has always been at the core of Houston's space industry. And this isn't going to change as commercialization within the sector continues.

"I think we'll be Space City forever," Hury says on the show. "We have a whole lot of expertise here that can support this new economy."

He shares more on the future of space health and Houston's role in space exploration on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


The new program will work with commercial spaceflight crews to bring back crucial research to one database. Photo via NASA/Unsplash

Houston organization launches the first commercial spaceflight medical research program

out of this world health care

With commercial space activity reaching cruising altitude, a Houston space health research organization has introduced a new program to create a centralized database.

The Translational Research Institute for Space Health, or TRISH, at Baylor College of Medicine announced a unique program that will work with commercial spaceflight providers and their passengers. The EXPAND — Enhancing eXploration Platforms and Analog Definition — Program will collect information and data from multiple space flights and organize it in one place. TRISH selected TrialX to build the centralized database.

As a partner to the NASA Human Research Program, the Houston-based organization's mission is to reduce health risks for astronauts and uncover advances for terrestrial healthcare, according to a news release.

"The space environment causes rapid body changes. This can help us understand how we humans react to and overcome stress. Ensuring that space explorers remain healthy pushes us to invent new approaches for early detection and prevention of medical conditions," says Dorit Donoviel, executive director at TRISH, in the release. "Studying a broad range of people in space increases our knowledge of human biology. TRISH's EXPAND program will leverage opportunities with commercial spaceflight providers and their willing crew to open up new research horizons."

The new collaborative program is meant to address the challenges that humans face on space missions — early detection and treatment of medical conditions, protection from radiation, mental health, team dynamics, and more. TRISH has been working on these challenges since its inception.

"This ground-breaking research model is only possible because everyone — scientists, commercial spaceflight companies, and passengers - recognizes the importance of space health research, and what we can learn by working together," says Dr. Emmanuel Urquieta, TRISH's chief medical officer, in the release.

EXPAND's first collaboration is the Inspiration4 mission, which is launching on September 15. The all-civilian crew will perform a variety of TRISH-supported human health experiments during their time in orbit.

"Shorter commercial space flights like Inspiration4 have similarities to early NASA Artemis missions," says Jimmy Wu, TRISH's senior biomedical engineer. "This allows TRISH an opportunity to test new health and performance technologies for future NASA astronauts."

The potential impact of innovation with this new centralized database and biobank is profound, says James Hury, TRISH's deputy director and chief innovation officer.

"The EXPAND database has the flexibility to seamlessly take in multiple types of data from different flight providers in order to create a repository that can integrate information," says Hury in the release. "A centralized, standardized research database and biobank will increase access to knowledge about human health for the global research community."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings